Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sino Biopharmaceutical ( (HK:1177) ) has shared an update.
Sino Biopharmaceutical Limited announced that its Investigational New Drug (IND) application for TQF3250, an innovative oral GLP-1 receptor agonist for type 2 diabetes, has been accepted by China’s National Medical Products Administration. The drug shows promising preclinical results, offering significant advantages in patient compliance and safety over existing injectable formulations. With the global GLP-1RA market expected to grow significantly, the acceptance of TQF3250 positions the company to potentially capture a share of this expanding market.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$9.80 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the biopharmaceutical industry. It specializes in the development of innovative drugs, particularly targeting diseases such as type 2 diabetes.
YTD Price Performance: 168.06%
Average Trading Volume: 175,067,202
Technical Sentiment Signal: Buy
Current Market Cap: HK$151.3B
For detailed information about 1177 stock, go to TipRanks’ Stock Analysis page.